Location History:
- Anhui, CN (2021 - 2022)
- Hefei, CN (2013 - 2023)
Company Filing History:
Years Active: 2013-2023
Title: Guangwei He: Innovator in Pharmaceutical Chemistry
Introduction
Guangwei He is a prominent inventor based in Hefei, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds for medical applications. With a total of 4 patents to his name, He continues to push the boundaries of pharmaceutical research.
Latest Patents
One of Guangwei He's latest patents is titled "PARP/PI3K double-target inhibit containing pyridopyrimidine structure." This patent focuses on a class of inhibitors that target both PARP and PI3K, which are crucial in cancer treatment. The compounds developed under this patent have shown promising results in pharmacodynamic tests, demonstrating their potential as anti-tumor agents. Another notable patent is for a "Compound pharmaceutical composition for treating skin inflammatory diseases." This composition combines tofacitinib and crisaborole, resulting in a stronger therapeutic effect with a lower dosage, showcasing a significant synergistic effect in treating skin conditions.
Career Highlights
Guangwei He has worked with notable companies such as Hefei Industrial Pharmaceutical Institute Co., Ltd and Hefei Amvite Pharmaceutical Co., Ltd. His experience in these organizations has allowed him to refine his expertise in pharmaceutical technology and contribute to various innovative projects.
Collaborations
He has collaborated with esteemed colleagues, including Zhaoxing Chu and Qinlong Xu. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical solutions.
Conclusion
Guangwei He is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in the treatment of various diseases. His innovative patents and collaborations reflect his commitment to improving healthcare through scientific research.